Study of Doxycycline to Prevent Gonorrhea, Chlamydia, and Syphilis in Men Who Have Sex With Men in Bangkok, Thailand

What this Trial Is About

Researchers are evaluating the effectiveness and safety of doxycycline to prevent sexually transmitted infections STIs such as gonorrhea, chlamydia, and syphilis among men who have sex with men MSM in Thailand. This Phase 4 study aims to understand if doxycycline post-exposure prophylaxis DoxyPEP can reduce the risk of these infections in this population. The study is sponsored by the Bangrak STIs Center and focuses on men aged 18 to 60 who are at risk for STIs. Participants will be randomly assigned to one of two groups one group will receive DoxyPEP, which involves taking a single dose of 200 mg doxycycline within 24 to 72 hours after unprotected sex, while the other group will receive standard STI prevention without doxycycline. The study includes a treatment period of approximately 12 weeks. During the study, participants will have 2 to 3 clinic visits and 10 to 11 follow-up phone calls over about 11 weeks. Researchers will monitor adherence to doxycycline use and conduct regular testing for gonorrhea, chlamydia, and syphilis to assess the treatments preventive effects. The primary outcome is to evaluate doxycyclines efficacy in preventing these infections within the 12-week study period.

The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.